Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

HC Wainwright assumed coverage on Ultragenyx Pharmaceuticals, Inc. RARE on Monday, representing an attractive opportunity at current levels.Analyst Raghuram Selvaraju notes that Ultragenyx stock is down 35% year to date, compared to a 2.7% decline in the benchmark XBI index.“Intriguing buying opportunity in one of biopharma’s most diversified rare disease-focused companies,” the analyst said.HC Wainwright assumed coverage at a Buy rating with a price target of $80.The analyst says Ultragenyx shares have pri ...